-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Hold on Neumora Therapeutics, Raises Price Target to $3

Benzinga·11/17/2025 13:52:02
Listen to the news
Stifel analyst Paul Matteis maintains Neumora Therapeutics (NASDAQ:NMRA) with a Hold and raises the price target from $2 to $3.